Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026
Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.